Below you'll find a list of all posts that have been tagged as “Pharma & Biotech”
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A pharmaceutical company needed more than a snapshot of competitor sales forces. Sedulo designed a continuous oncology intelligence program that tracked how seven key competitors were structuring, scaling, and deploying commercial resources, delivering the early signals needed to sharpen share-of-voice strategy and commercial planning.
The life sciences organizations that consistently make better decisions aren’t necessarily the ones with the most data, they’re the ones that have built competitive intelligence into the fabric of how they plan and act. Drawing on primary research, expert interviews, and Sedulo Group’s Annual Life Sciences CI Survey, this post outlines five practical recommendations for elevating CI from a reporting function to a true driver of strategic impact.
A leading pharmaceutical company partnered with Sedulo Group to build a continuous competitive intelligence program tracking innovators, biosimilars, and emerging therapies across the rapidly evolving insulin market. The engagement combined ongoing competitor monitoring, primary intelligence, and quarterly landscape reporting to support stronger portfolio decisions and confident preparation for new market entrants.
A global pharmaceutical company partnered with Sedulo to gain continuous visibility into competitive dynamics across four therapeutic areas. The result was faster BD scouting, clearer portfolio prioritization, and more confident strategic decisions.
A biopharma leader partnered with Sedulo on a multi-year competitive intelligence program to connect early clinical signals with commercial strategy. The engagement delivered continuous insights across 10 rare disease areas, enabling faster decisions, earlier warnings, and confident portfolio planning.
Facing intensifying competition in the metabolic therapeutics arena, the pharma leader needed clear foresight into biosimilar threats, innovation pipelines, and competitor launch tactics. Through early-warning monitoring, primary intelligence, and deep landscape reporting, we helped them anticipate market shifts, align internal decision-makers, and fortify their leadership ahead of emerging disruptions.
A top pharmaceutical company partnered with Sedulo Group to leverage pharma competitive intelligence and outmaneuver competitors in a high-stakes product launch.
Sedulo crafted an early-warning monitoring program for a pharma leader focused on Parkinson’s stage therapies. Through secondary intelligence (press releases, clinical data) and primary interviews with competitor personnel, the team flagged key R&D moves, enabling the client to pivot proactively in a fast-evolving treatment space
